Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer

European Journal of Pharmacology

Volumn 754, Issue , 2015, Pages 82-91

  Haghgoo, Seyyed Mortaza ^a   Allameh, Abdolamir ^a   Mortaz, Esmaeil ^b,c,d,e   Garssen, Johan ^e,f   Folkerts, Gert ^e   Barnes, Peter J ^b   Adcock, Ian M ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e UTRECHT UNIVERSITY   (Netherlands)

^f Nutricia Nederland   (Netherlands)

Author keywords

EGFR; K Ras mutations; Lung cancer; NSCLC

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; GENETIC VARIABILITY; HUMAN; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TUMOR INVASION; ANIMAL; BIOLOGICAL MODEL; CANCER STEM CELL; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS;

EID: 84924080670     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.02.029     Document Type: Review

References (139)

1. Food and Drug Administration (FaD), 2013. November 2013 PMA Approvals. U.S. Food and Drug Administration, USA.
2. A. Balmain, J. Gray, and B. Ponder The genetics and genomics of cancer Nat. Genet. 33 2003 238 244
3. U. Banerji Heat shock protein 90 as a drug target: some like it hot Clin. Cancer Res. 15 2009 9 14
4. K. Bergethon, A.T. Shaw, S.-H. Ou, R. Katayama, C.M. Lovly, N.T. McDonald, P.P. Massion, C. Siwak-Tapp, A. Gonzalez, R. Fang, E.J. Mark, J.M. Batten, H. Chen, K.D. Wilner, E.L. Kwak, J.W. Clark, D.P. Carbone, H. Ji, J.A. Engelman, M. Mino-Kenudson, W. Pao, and A.J. Iafrate ROS1 rearrangements define a unique molecular class of lung cancers J. Clin. Oncol. 30 2012 863 870
5. G. Bertolini, L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti, G. Pratesi, A. Fabbri, F. Andriani, S. Tinelli, E. Roz, R. Caserini, S. Lo Vullo, T. Camerini, L. Mariani, D. Delia, E. Calabrò, U. Pastorino, and G. Sozzi Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment Proc. Natl. Acad. Sci. 106 2009 16281 16286
6. C. Birchmeier, D. Birnbaum, G. Waitches, O. Fasano, and M. Wigler Characterization of an activated human ros gene Mol. Cell. Biol. 6 1986 3109 3116
7. C. Birchmeier, S. Sharma, and M. Wigler Expression and rearrangement of the ROS1 gene in human glioblastoma cells Proc. Natl. Acad. Sci. 84 1987 9270 9274
8. M. Blum, A. Demierre, D.M. Grant, M. Heim, and U.A. Meyer Molecular mechanism of slow acetylation of drugs and carcinogens in humans Proc. Natl. Acad. Sci. U.S.A. 88 1991 5237 5241
9. M. Brevet, M. Arcila, and M. Ladanyi Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR J. Mol. Diagnost. 12 2010 169 176
10. M.S. Brose, P. Volpe, M. Feldman, M. Kumar, I. Rishi, R. Gerrero, E. Einhorn, M. Herlyn, J. Minna, A. Nicholson, J.A. Roth, S.M. Albelda, H. Davies, C. Cox, G. Brignell, P. Stephens, P.A. Futreal, R. Wooster, M.R. Stratton, and B.L. Weber BRAF and RAS mutations in human lung cancer and melanoma Cancer Res. 62 2002 6997 7000
11. W. Brugger, and M. Thomas EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment Lung Cancer 77 2012 2 8
12. D.R. Camidge, and R.C. Doebele Treating ALK-positive lung cancer[mdash]early successes and future challenges Nat. Rev. Clin. Oncol. 9 2012 268 277
13. P. Carmeliet, and R.K. Jain Molecular mechanisms and clinical applications of angiogenesis Nature 473 2011 298 307
14. P.E. Carson, C.L. Flanagan, C.E. Ickes, and A.S. Alving Enzymatic deficiency in primaquine-sensitive erythrocytes Science 124 1956 484 485
15. R. Charlab, and L. Zhang Pharmacogenomics: historical perspective and current status F. Innocenti, R.H.N. Schaik, Pharmacogenomics 2013 Humana Press 3 22
16. R. Chiarle, C. Voena, C. Ambrogio, R. Piva, and G. Inghirami The anaplastic lymphoma kinase in the pathogenesis of cancer Nat. Rev. Cancer 8 2008 11 23
17. Y.L. Choi, M. Soda, Y. Yamashita, T. Ueno, J. Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, H. Haruta, Y. Ishikawa, H. Kimura, T. Mitsudomi, Y. Tanio, and H. Mano EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N. Engl. J. Med. 363 2010 1734 1739
18. J.G. Christensen, J. Burrows, and R. Salgia c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention Cancer Lett. 225 2005 1 26
19. C.B. Clayman, J. Arnold, R.S. Hockwald, E.H. Yount, J.H. Edgcomb, and A.S. Alving Toxicity of primaquine in caucasians J. Am. Med. Assoc. 149 1952 1563 1568
20. H. Clevers The cancer stem cell: premises, promises and challenges Nat. Med. 17 2011 313 319
21. M.P. Coleman Cancer survival: global surveillance will stimulate health policy and improve equity Lancet 383 2014 564 573
22. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W.C. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, and P.A. Futreal Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
23. K.D. Davies, A.T. Le, M.F. Theodoro, M.C. Skokan, D.L. Aisner, E.M. Berge, L.M. Terracciano, F. Cappuzzo, M. Incarbone, M. Roncalli, M. Alloisio, A. Santoro, D.R. Camidge, M. Varella-Garcia, and R.C. Doebele Identifying and targeting ROS1 gene fusions in non-small cell lung cancer Clin. Cancer Res. 18 2012 4570 4579
24. A. Eramo, F. Lotti, G. Sette, E. Pilozzi, M. Biffoni, A. Di Virgilio, C. Conticello, L. Ruco, C. Peschle, and R. De Maria Identification and expansion of the tumorigenic lung cancer stem cell population Cell Death Differ. 15 2007 504 514
25. D.A.P. Evans, K.A. Manley, and V.A. McKusick Genetic control of isoniazid metabolism in man Br. Med. J. 2 1960 485
26. X. Fan, W. Matsui, L. Khaki, D. Stearns, J. Chun, Y.-M. Li, and C.G. Eberhart Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors Cancer Res. 66 2006 7445 7452
27. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, R. Kudchadkar, H.A. Burris, G. Falchook, A. Algazi, K. Lewis, G.V. Long, I. Puzanov, P. Lebowitz, A. Singh, S. Little, P. Sun, A. Allred, D. Ouellet, K.B. Kim, K. Patel, and J. Weber Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N. Engl. J. Med. 367 2012 1694 1703
28. Food and Drug Administration Cabozantinib 2012 U. S. Food and Drug Administration USA
29. ® EGFR Mutation Test - P120019 2013 U.S. Food and Drug Administration USA
30. Food and Drug Administration Crizotinib 2013 U. S. Food and Drug Administration USA
31. ® EGFR RGQ PCR Kit - P120022 2013 U.S. Food and Drug Administration USA
32. Food and Drug Administration Ceritinib 2014 U. S. Food and Drug Administration USA
33. S.M. Gadgeel, M.L. Cote, A.G. Schwartz, L.H. Matherly, A. Wozniak, and G. Bepler Parameters for individualizing systemic therapy in non-small cell lung cancer Drug Resist. Updates 13 2010 196 204
34. J.F. Gainor, and A.T. Shaw Novel targets in non-small cell lung cancer: ROS1 and RET fusions Oncologist 18 2013 865 875
35. D.E. Gerber Targeted therapies: a new generation of cancer treatments Am. Fam. Physician 77 2008 311 319
36. C. Gridelli, S. Peters, A. Sgambato, F. Casaluce, A.A. Adjei, and F. Ciardiello ALK inhibitors in the treatment of advanced NSCLC Cancer Treat. Rev. 40 2014 300 306
37. M. Grieco, M. Santoro, M.T. Berlingieri, R.M. Melillo, R. Donghi, I. Bongarzone, M.A. Pierotti, G. Della Ports, A. Fusco, and G. Vecchiot PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas Cell 60 1990 557 563
38. B. Hallberg, and R.H. Palmer Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology Nat. Rev. Cancer 13 2013 685 700
39. D. Hanahan Rethinking the war on cancer Lancet 383 2014 558 563
40. D. Hanahan, and Robert A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
41. J.M. Heuckmann, D. Rauh, and R.K. Thomas Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer J. Clin. Oncol. 30 2012 3417 3420
42. E.H. Huang, M.J. Hynes, T. Zhang, C. Ginestier, G. Dontu, H. Appelman, J.Z. Fields, M.S. Wicha, and B.M. Boman Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis Cancer Res. 69 2009 3382 3389
43. T. Huang, M. Karsy, J. Zhuge, M. Zhong, and D. Liu B-Raf and the inhibitors: from bench to bedside J. Hematol. Oncol. 6 2013 30
44. H.B. Hughes, J. Biehl, A. Jones, and L. Schmidt Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis Am. Rev. Tuberc. 70 1954 266
45. P.W. Ingham, and A.P. McMahon Hedgehog signaling in animal development: paradigms and principles Genes Dev. 15 2001 3059 3087
46. T.W. Jang, C.H. Oak, H.K. Chang, S.J. Suo, and M.H. Jung EGFR and KRAS mutations in patients with adenocarcinoma of the lung Korean J. Intern. Med. 24 2009 48 54
47. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
48. H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, A. Protopopov, B.L. Jung, K. McNamara, H. Xia, K.A. Glatt, R.K. Thomas, H. Sasaki, J.W. Horner, M. Eck, A. Mitchell, Y. Sun, R. Al-Hashem, R.T. Bronson, S.K. Rabindran, C.M. Discafani, E. Maher, G.I. Shapiro, M. Meyerson, and K.-K. Wong Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors Proc. Natl. Acad. Sci. 103 2006 7817 7822
49. F. Jiang, Q. Qiu, A. Khanna, N.W. Todd, J. Deepak, L. Xing, H. Wang, Z. Liu, Y. Su, S.A. Stass, and R.L. Katz Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer Mol. Cancer Res. 7 2009 330 338
50. Y.S. Ju, W.-C. Lee, J.-Y. Shin, S. Lee, T. Bleazard, J.-K. Won, Y.T. Kim, J.-I. Kim, J.-H. Kang, and J.-S. Seo A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing Genome Res. 22 2012 436 445
51. T. Klonisch, E. Wiechec, S. Hombach-Klonisch, S.R. Ande, S. Wesselborg, K. Schulze-Osthoff, and M. Los Cancer stem cell markers in common cancers - therapeutic implications Trends Mol. Med. 14 2008 450 460
52. T. Kohno, H. Ichikawa, Y. Totoki, K. Yasuda, M. Hiramoto, T. Nammo, H. Sakamoto, K. Tsuta, K. Furuta, Y. Shimada, R. Iwakawa, H. Ogiwara, T. Oike, M. Enari, A.J. Schetter, H. Okayama, A. Haugen, V. Skaug, S. Chiku, I. Yamanaka, Y. Arai, S.-i. Watanabe, I. Sekine, S. Ogawa, C.C. Harris, H. Tsuda, T. Yoshida, J. Yokota, and T. Shibata KIF5B-RET fusions in lung adenocarcinoma Nat. Med. 18 2012 375 377
53. E.L. Kwak, Y.-J. Bang, D.R. Camidge, A.T. Shaw, B. Solomon, R.G. Maki, S.-H.I. Ou, B.J. Dezube, P.A. Jänne, D.B. Costa, M. Varella-Garcia, W.-H. Kim, T.J. Lynch, P. Fidias, H. Stubbs, J.A. Engelman, L.V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G.C. Wei, S.M. Shreeve, M.J. Ratain, J. Settleman, J.G. Christensen, D.A. Haber, K. Wilner, R. Salgia, G.I. Shapiro, J.W. Clark, and A.J. Iafrate Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 363 2010 1693 1703
54. D. Lambrechts, H.-J. Lenz, S. de Haas, P. Carmeliet, and S.J. Scherer Markers of response for the antiangiogenic agent bevacizumab J. Clin. Oncol. 31 2013 1219 1230
55. F. Li, Y. Feng, R. Fang, Z. Fang, J. Xia, X. Han, X.Y. Liu, H. Chen, H. Liu, and H. Ji Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers Cell Res. 22 2012 928 931
56. H. Linardou, I.J. Dahabreh, D. Bafaloukos, P. Kosmidis, and S. Murray Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC Nat. Rev. Clin. Oncol. 6 2009 352 366
57. H. Linardou, I.J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, P. Kosmidis, C.A. Papadimitriou, and S. Murray Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol. 9 2008 962 972
58. S. Liu, G. Dontu, I.D. Mantle, S. Patel, N.-s. Ahn, K.W. Jackson, P. Suri, and M.S. Wicha Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells Cancer Res. 66 2006 6063 6071
59. C.Y. Logan, and R. Nusse The Wnt signaling pathway in development and disease Annu. Rev. Cell Dev. Biol. 20 2004 781 810
60. C.M. Lovly, and D.P. Carbone Lung cancer in 2010: one size does not fit all Nat. Rev. Clin. Oncol. 8 2011 68 70
61. J. Luo, N.L. Solimini, and S.J. Elledge Principles of cancer therapy: oncogene and non-oncogene addiction Cell 136 2009 823 837
62. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
63. M. Macaluso, G. Russo, C. Cinti, V. Bazan, N. Gebbia, and A. Russo Ras family genes: an interesting link between cell cycle and cancer J. Cell. Physiol. 192 2002 125 130
64. I. Malanchi, H. Peinado, D. Kassen, T. Hussenet, D. Metzger, P. Chambon, M. Huber, D. Hohl, A. Cano, W. Birchmeier, and J. Huelsken Cutaneous cancer stem cell maintenance is dependent on [bgr]-catenin signalling Nature 452 2008 650 653
65. J.L. Marks, S. Broderick, Q. Zhou, D. Chitale, A.R. Li, M.F. Zakowski, M.G. Kris, V.W. Rusch, C.G. Azzoli, V.E. Seshan, M. Ladanyi, and W. Pao Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J. Thorac. Oncol. 3 2008 111 116
66. M.P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro, D. Conte, P. Gasparini, F. Perrone, P. Modena, U. Pastorino, A. Carbone, A. Fabbri, A. Sidoni, S. Nakamura, M. Gambacorta, P.L. Fernández, J. Ramirez, J.K.C. Chan, W.F. Grigioni, E. Campo, S.A. Pileri, and B. Falini EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues Am. J. Pathol. 174 2009 661 670
67. E. Massarelli, M. Varella-Garcia, X. Tang, A.C. Xavier, N.C. Ozburn, D.D. Liu, B.N. Bekele, R.S. Herbst, and I.I. Wistuba KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin. Cancer Res. 13 2007 2890 2896
68. G. Maulik, A. Shrikhande, T. Kijima, P.C. Ma, P.T. Morrison, and R. Salgia Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition Cytokine Growth Factor Rev. 13 2002 41 59
69. U. McDermott, A.J. Iafrate, N.S. Gray, T. Shioda, M. Classon, S. Maheswaran, W. Zhou, H.G. Choi, S.L. Smith, L. Dowell, L.E. Ulkus, G. Kuhlmann, P. Greninger, J.G. Christensen, D.A. Haber, and J. Settleman Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors Cancer Res. 68 2008 3389 3395
70. A. McErlean, and M.S. Ginsberg Epidemiology of lung cancer Semin. Roentgenol. 46 2011 173 177
71. G. Metro, and L. Crinò The LUX-lung clinical trial program of afatinib for non-small-cell lung cancer Expert Rev. Anticancer Ther. 11 2011 673 682
72. U.A. Meyer Pharmacogenetics and adverse drug reactions Lancet 356 2000 1667 1671
73. U.A. Meyer Pharmacogenetics - five decades of therapeutic lessons from genetic diversity Nat. Rev. Genet. 5 2004 669 676
74. U.A. Meyer, and U.M. Zanger Molecular mechanisms of genetic polymorphisms of drug methabolism Annu. Rev. Pharmacol. Toxicol. 37 1997 269 296
75. L. Miele Notch signaling Clin. Cancer Res. 12 2006 1074 1079
76. J. Minna, and J. Schiller Neoplasms of the lung D. Kasper, D. Longo, E. Braunwald, S. Hauser, J. Jameson, J. Loscalzo, Harison's Principles of Internal Medicine 17th ed. 2008 McGraw-Hill Companies New York, Chicago, San Francisco, Lisbon, London, Madrid, Mexico City, New Delhi, San Juan, Seoul, Singapore, Sydney, Toronto 551 562
77. N. Mitin, K.L. Rossman, and C.J. Der Signaling interplay in Ras superfamily function Curr. Biol. 15 2005 R563 R574
78. T.S.K. Mok Personalized medicine in lung cancer: what we need to know Nat. Rev. Clin. Oncol. 8 2011 661 668
79. P. Morin, J. Trent, F. Collins, and B. Vogelstein Cancer genetics D. Kasper, D. Longo, E. Braunwald, S. Hauser, J. Jameson, J. Loscalzo, Harison's Principles of Internal Medicine 17th ed. 2008 McGraw-Hill Companies New York, Chicago, San Francisco, Lisbon, London, Madrid, Mexico City, New Delhi, San Juan, Seoul, Singapore, Sydney, Toronto 492 498
80. L. Nagarajan, E. Louie, Y. Tsujimoto, P.C. Balduzzi, K. Huebner, and C.M. Croce The human c-ros gene (ROS) is located at chromosome region 6q16-6q22 Proc. Natl. Acad. Sci. 83 1986 6568 6572
81. D.W. Nebert, G. Zhang, and E.S. Vesell From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions Drug Metab. Rev. 40 2008 187 224
82. J.D. O'Flaherty, M. Barr, D. Fennell, D. Richard, J. Reynolds, J. O'Leary, and K. O'Byrne The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy J. Thorac. Oncol. 7 2012 1880 1890
83. K. Ohtsuka, H. Ohnishi, M. Fujiwara, T. Kishino, S. Matsushima, G. Furuyashiki, H. Takei, Y. Koshiishi, T. Goya, and T. Watanabe Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas Cancer 109 2007 741 750
84. J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
85. P.K. Paik, M.E. Arcila, M. Fara, C.S. Sima, V.A. Miller, M.G. Kris, M. Ladanyi, and G.J. Riely Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations J. Clin. Oncol. 29 2011 2046 2051
86. W. Pao, and J. Chmielecki Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat. Rev. Cancer 10 2010 760 774
87. W. Pao, V.A. Miller, K.A. Politi, G.J. Riely, R. Somwar, M.F. Zakowski, M.G. Kris, and H. Varmus Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 2005 e73
88. W. Pao, T.Y. Wang, G.J. Riely, V.A. Miller, Q. Pan, M. Ladanyi, M.F. Zakowski, R.T. Heelan, M.G. Kris, and H.E. Varmus KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med. 2 2005 0057 0061
89. R. Pardal, M.F. Clarke, and S.J. Morrison Applying the principles of stem-cell biology to cancer Nat. Rev. Cancer 3 2003 895 902
90. C.A. Perez, M. Velez, L.E. Raez, and E.S. Santos Overcoming the resistance to Crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation Lung Cancer 84 2014 110 115
91. E.D. Pleasance, R.K. Cheetham, P.J. Stephens, D.J. McBride, S.J. Humphray, C.D. Greenman, I. Varela, M.-L. Lin, G.R. Ordonez, G.R. Bignell, K. Ye, J. Alipaz, M.J. Bauer, D. Beare, A. Butler, R.J. Carter, L. Chen, A.J. Cox, S. Edkins, P.I. Kokko-Gonzales, N.A. Gormley, R.J. Grocock, C.D. Haudenschild, M.M. Hims, T. James, M. Jia, Z. Kingsbury, C. Leroy, J. Marshall, A. Menzies, L.J. Mudie, Z. Ning, T. Royce, O.B. Schulz-Trieglaff, A. Spiridou, L.A. Stebbings, L. Szajkowski, J. Teague, D. Williamson, L. Chin, M.T. Ross, P.J. Campbell, D.R. Bentley, P.A. Futreal, and M.R. Stratton A comprehensive catalogue of somatic mutations from a human cancer genome Nature 463 2010 191 196
92. M. Reck, D.F. Heigener, T. Mok, J.-C. Soria, and K.F. Rabe Management of non-small-cell lung cancer: recent developments Lancet 382 2013 709 719
93. T. Reya, and H. Clevers Wnt signalling in stem cells and cancer Nature 434 2005 843 850
94. G.J. Riely, J. Marks, and W. Pao KRAS mutations in non-small cell lung cancer Proc. Am. Thorac. Soc. 6 2009 201 205
95. P.J. Roberts Clinical use of crizotinib for the treatment of non-small cell lung cancer Biologics: Targets Ther. 7 2013 91 101
96. R. Roskoski Jr The ErbB/HER family of protein-tyrosine kinases and cancer Pharmacol. Res. 79 2014 34 74
97. A. Rossi, and M. Di Maio LUX-Lung: determining the best EGFR inhibitor in NSCLC? Lancet Oncol. 16 2 2015 118 119
98. A. Sahu, K. Prabhash, V. Noronha, A. Joshi, and S. Desai Crizotinib: a comprehensive review S. Asian J. Cancer 2 2013 91 97
99. H. Sasaki, O. Kawano, K. Endo, H. Yukiue, M. Yano, and Y. Fujii EGFRvIII mutation in lung cancer correlates with increased EGFR copy number Oncol. Rep. 17 2007 319 323
100. T. Sasaki, S.J. Rodig, L.R. Chirieac, and P.A. Jänne The biology and treatment of EML4-ALK non-small cell lung cancer Eur. J. Cancer 46 2010 1773 1780
101. A. Savonarola, R. Palmirotta, F. Guadagni, and F. Silvestris Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy Pharmacogenomics J. 12 2012 277 286
102. K. Schmid, N. Oehl, F. Wrba, R. Pirker, C. Pirker, and M. Filipits EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases Clin. Cancer Res. 15 2009 4554 4560
103. M.R. Schneider, and E. Wolf The epidermal growth factor receptor ligands at a glance J. Cell. Physiol. 218 2009 460 466
104. M. Shackleton, E. Quintana, E.R. Fearon, and S.J. Morrison Heterogeneity in cancer: cancer stem cells versus clonal evolution Cell 138 2009 822 829
105. S.V. Sharma, D.W. Bell, J. Settleman, and D.A. Haber Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 7 2007 169 181
106. S.V. Sharma, D.W. Bell, J. Settleman, and D.A. Haber Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 7 2007 169 181
107. S.V. Sharma, and J. Settleman ErbBs in lung cancer Exp. Cell Res. 315 2009 557 571
108. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson, S.R. Digumarthy, D.B. Costa, R.S. Heist, B. Solomon, H. Stubbs, S. Admane, U. McDermott, J. Settleman, S. Kobayashi, E.J. Mark, S.J. Rodig, L.R. Chirieac, E.L. Kwak, T.J. Lynch, and A.J. Iafrate Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J. Clin. Oncol. 27 2009 4247 4253
109. H. Shigematsu, and A.F. Gazdar Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers Int. J. Cancer 118 2006 257 262
110. Y.-S. Shinh, C.-Y. Lai, Y.-R. Kao, S.-G. Shiah, Y.-W. Chu, H.-S. Lee, and C.-W. Wu Expression of Axl in lung adenocarcinoma and correlation with tumor progression Neoplasia 7 2005 1058 1064
111. M. Soda, Y.L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S.-i. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, and H. Mano Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
112. B.J. Solomon, T. Mok, D.-W. Kim, Y.-L. Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, S. Iyer, A. Reisman, K.D. Wilner, J. Tursi, and F. Blackhall First-line crizotinib versus chemotherapy in ALK-positive lung cancer N. Engl. J. Med. 371 2014 2167 2177
113. D.J. Stewart, E. Tomiak, F.M. Shamji, D.E. Maziak, and P. MacLeod Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer Lung Cancer 44 2004 241 249
114. M.R. Stratton, P.J. Campbell, and P.A. Futreal The cancer genome Nature 458 2009 719 724
115. M. Takahashi, J. Ritz, and G.M. Cooper Activation of a novel human transforming gene, ret, by DNA rearrangement Cell 42 1985 581 588
116. K. Takeuchi, M. Soda, Y. Togashi, R. Suzuki, S. Sakata, S. Hatano, R. Asaka, W. Hamanaka, H. Ninomiya, H. Uehara, Y. Lim Choi, Y. Satoh, S. Okumura, K. Nakagawa, H. Mano, and Y. Ishikawa RET, ROS1 and ALK fusions in lung cancer Nat. Med. 18 2012 378 381
117. A. Tomas, C.E. Futter, and E.R. Eden EGF receptor trafficking: consequences for signaling and cancer Trends Cell Biol 2013
118. T. Tsuruo Molecular cancer therapeutics: recent progress and targets in drug resistance Intern. Med. 42 2003 237 243
119. D. Tulasne, J. Deheuninck, F.C. Lourenco, F. Lamballe, Z. Ji, C. Leroy, E. Puchois, A. Moumen, F. Maina, P. Mehlen, and V. Fafeur Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage Mol. Cell. Biol. 24 2004 10328 10339
120. A. Vaishnavi, M. Capelletti, A.T. Le, S. Kako, M. Butaney, D. Ercan, S. Mahale, K.D. Davies, D.L. Aisner, A.B. Pilling, E.M. Berge, J. Kim, H. Sasaki, S.-i. Park, G. Kryukov, L.A. Garraway, P.S. Hammerman, J. Haas, S.W. Andrews, D. Lipson, P.J. Stephens, V.A. Miller, M. Varella-Garcia, P.A. Janne, and R.C. Doebele Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer Nat. Med. 19 2013 1469 1472
121. E. Vakiani, and D.B. Solit KRAS and BRAF: drug targets and predictive biomarkers J. Pathol. 223 2011 220 230
122. P. Valent, D. Bonnet, R. De Maria, T. Lapidot, M. Copland, J.V. Melo, C. Chomienne, F. Ishikawa, J.J. Schuringa, G. Stassi, B. Huntly, H. Herrmann, J. Soulier, A. Roesch, G.J. Schuurhuis, S. Wohrer, M. Arock, J. Zuber, S. Cerny-Reiterer, H.E. Johnsen, M. Andreeff, and C. Eaves Cancer stem cell definitions and terminology: the devil is in the details Nat. Rev. Cancer 12 2012 767 775
123. K.P. Vatsis, K.J. Martell, and W.W. Weber Diverse point mutations in the human gene for polymorphic N-acetyltransferase Proc. Natl. Acad. Sci. U.S.A. 88 1991 6333 6337
124. P.T.C. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, C.G. Project, C.M. Jones, C.J. Marshall, C.J. Springer, D. Barford, and R. Marais Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
125. L. Wang, H.L. McLeod, and R.M. Weinshilboum Genomics and drug response N. Engl. J. Med. 364 2011 1144 1153
126. R. Wang, H. Hu, Y. Pan, Y. Li, T. Ye, C. Li, X. Luo, L. Wang, H. Li, Y. Zhang, F. Li, Y. Lu, Q. Lu, J. Xu, D. Garfield, L. Shen, H. Ji, W. Pao, Y. Sun, and H. Chen RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer J. Clin. Oncol. 30 2012 4352 4359
127. W.H.J. Ward, P.N. Cook, A.M. Slater, D.H. Davies, G.A. Holdgate, and L.R. Green Epidermal growth factor receptor tyrosine kinase: investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor Biochem. Pharmacol. 48 1994 659 666
128. R.M. Weinshilboum, and L. Wang Pharmacogenetics and pharmacogenomics: development, science, and translation Annu. Rev. Genomics Hum. Genet. 7 2006 223 245
129. I.B. Weinstein Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis Carcinogenesis 21 2000 857 864
130. I.B. Weinstein Addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64
131. I.B. Weinstein, and A.K. Joe Mechanisms of disease: oncogene addiction[mdash]a rationale for molecular targeting in cancer therapy Nat. Clin. Pract. Oncol. 3 2006 448 457
132. K. Wennerberg, K.L. Rossman, and C.J. Der The Ras superfamily at a glance J. Cell Sci. 118 2005 843 846
133. M. Whirl-Carrillo, E.M. McDonagh, J.M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, R.B. Altman, and T.E. Klein Pharmacogenomics knowledge for personalized medicine Clin. Pharmacol. Ther. 92 2012 414 417
134. A.J. Wood, W.E. Evans, and H.L. McLeod Pharmacogenomics - drug disposition, drug targets, and side effects N. Engl. J. Med. 348 2003 538 549
135. H. Yasuda, L.L. de Figueiredo-Pontes, S. Kobayashi, and D.B. Costa Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer J. Thorac. Oncol.: official publication of the International Association for the Study of Lung Cancer 7 2012 1086 1090
136. A. Young, O. Chapman, C. Connor, C. Poole, P. Rose, and A.K. Kakkar Thrombosis and cancer Nat. Rev. Clin. Oncol. 9 2012 437 449
137. J. Yu, S. Kane, J. Wu, E. Benedettini, D. Li, C. Reeves, G. Innocenti, R. Wetzel, K. Crosby, A. Becker, M. Ferrante, W.C. Cheung, X. Hong, L.R. Chirieac, L.M. Sholl, H. Haack, B.L. Smith, R.D. Polakiewicz, Y. Tan, T.-L. Gu, M. Loda, X. Zhou, and M.J. Comb Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer Clin. Cancer Res. 15 2009 3023 3028
138. Z. Zhang, J.C. Lee, L. Lin, V. Olivas, V. Au, T. LaFramboise, M. Abdel-Rahman, X. Wang, A.D. Levine, J.K. Rho, Y.J. Choi, C.-M. Choi, S.-W. Kim, S.J. Jang, Y.S. Park, W.S. Kim, D.H. Lee, J.-S. Lee, V.A. Miller, M. Arcila, M. Ladanyi, P. Moonsamy, C. Sawyers, T.J. Boggon, P.C. Ma, C. Costa, M. Taron, R. Rosell, B. Halmos, and T.G. Bivona Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nat. Genet. 44 2012 852 860
139. W. Zhou, D. Ercan, L. Chen, C.-H. Yun, D. Li, M. Capelletti, A.B. Cortot, L. Chirieac, R.E. Iacob, R. Padera, J.R. Engen, K.-K. Wong, M.J. Eck, N.S. Gray, and P.A. Janne Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 2009 1070 1074